|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
7 April 2015 |
|
Main ID: |
NCT00004443 |
|
Date of registration:
|
18/10/1999 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Study of NTBC for Tyrosinemia I
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
October 1998 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00004443 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Canada
|
United States
| | | | | | |
|
Contacts
|
|
Name:
|
C. Ronald Scott |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Washington |
| | |
|
Key inclusion & exclusion criteria
|
- Confirmed diagnosis of tyrosinemia Detected through newborn screening before the
onset of symptoms OR Diagnosed on the basis of symptoms (liver disease, neurological
crises, growth failure) and succinylacetone in urine or blood and/or
fumarylacetoacetate dehydratase deficiency in cultured fibroblasts or liver biopsy
Age minimum:
N/A
Age maximum:
17 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Tyrosinemia I
|
|
Intervention(s)
|
|
Drug: NTBC
|
|
Secondary ID(s)
|
|
199/13443
|
|
UWASH-FDR001445
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|